Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can glasses that slow nearsightedness also reshape a Child's astigmatism?

NCT ID NCT07810725

Disease control Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

Researchers are studying whether spectacle lenses designed to slow myopia progression affect astigmatism in children aged 6 to 13 who have both myopia and astigmatism. All participants wear the study lenses daily for one year and visit the Essilor R&D Centre for follow-up eye measurements. The trial tracks changes in astigmatism, corneal curvature, eye length, and quality of life to see how the eye responds to the lenses over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lenslet-based myopia control spectacle lens
What this could lead to
If the lenses slow myopia without worsening astigmatism, eye doctors could prescribe them with more confidence for children who have both conditions.
What could go wrong
The trial is small and single-arm, so it cannot prove the lenses cause any change. Astigmatism often shifts naturally as children grow, which makes the results hard to interpret.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 13 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Volunteer participant * Informed consent of parent or guardian and assent of participant * Age equal to or greater than 6 years and less than 13 years (before 13th birthday) at the time of consent. * Refractive error (manifest refraction): * With the rule astigmatism (defined as vertical meridian has steeper curvature, Astigmatism prescribing axis in between: 0 to 34° and 146 to 180°) * Astigmatism should be more than or equal to 1.50D * Least myopic meridian equal or less than -0.50D * Most myopic meridian equal or greater than -5.50D. * Anisometropia should be less than or equal to 1.00D * Best corrected visual acuity: Better than 0.2 logMAR in each eye * Willingness and ability to: * participate in trial for at least 12 months. * attend scheduled visits. * not to be involved in other myopia control treatments concurrently. * No history of any myopia control interventions (i.e., myopia control spectacle lenses, myopia control contact lenses, orthokeratology lenses or atropine, etc.) Exclusion Criteria: * History or presence of: * An ocular disease * Strabismus * Amblyopia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Astigmatism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astigmatism myopia regular astigmatism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Astigmatism Myopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.